Related Experiment Video
Updated: Feb 9, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Combination therapy in the treatment of hypertension
Carolina Guerrero-García1,2, Alberto Francisco Rubio-Guerra1,2
1Unidad de Investigación Clínico-Metabólica, Hospital General de Ticomán SS DF, Mexico City, Mexico.
Insights
Achieving optimal blood pressure control often requires combination therapy for hypertension. Recent guidelines suggest starting with two drugs for many patients, with some needing three to reach treatment goals.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Hypertension is a significant, modifiable risk factor for atherosclerosis and ischemic heart disease.
- Despite available antihypertensive medications, many patients do not achieve optimal blood pressure control.
- Current treatment guidelines advocate for combination therapy in specific patient groups.
Purpose of the Study:
- To review the latest evidence on combination therapy for hypertension management.
- To highlight the necessity of multi-drug regimens for achieving therapeutic blood pressure goals.
Main Methods:
- Literature review of recent studies and guidelines on hypertension treatment.
- Analysis of data concerning the efficacy and necessity of combination antihypertensive agents.
Main Results:
- A substantial proportion of hypertensive patients require more than one medication to control blood pressure.
- Guidelines recommend initiating two-drug therapy for patients significantly above their blood pressure goals or at high cardiovascular risk.
- Around 25% of patients may need three antihypertensive agents to achieve target blood pressure levels.
Conclusions:
- Combination therapy is frequently essential for effective hypertension management.
- Adherence to guidelines for initiating multi-drug regimens can improve patient outcomes.
- Further research into optimizing combination therapy strategies is warranted.
Abstract:
Hypertension is a major preventable risk factor for atherosclerosis and ischemic heart disease. Although modern and effective antihypertensive drugs are available, most patients remain with a suboptimal blood pressure control. Most hypertensive patients will need a combination of antihypertensive agents to achieve the therapeutic goals - recent guidelines recommend initiating treatment with two drugs in those patients with a systolic blood pressure >20 mmHg and/or a diastolic blood pressure >10 mmHg above the goals, and in those patients with high cardiovascular risk. In addition, approximately 25% of patients will require three antihypertensive agents to achieve the therapeutic targets. In this review, we analyse the latest information available regarding the treatment of hypertension with combination therapy.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Hypertension IV: Drug Therapy and Lifestyle Modifications
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

